Neal Ready et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14(2), 237-244 (2018-10-14)
For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors previously